Optimal Blood Test to Help Develop Novel Alzheimer's Disease Diagnostics

Blood biomarkers of Alzheimer's disease pathology are altered both preclinically and throughout the disease's symptomatic phase, and unique biomarkers may be the best way to diagnose or monitor disease progression. When disease-modifying therapies are approved for use, validated blood-based biomarkers may be able to help guide their implementation and further management in clinical practice. Blood biomarkers associated with changes in cognition and brain atrophy during disease onset may be used in clinical trials to identify successful interventions and accelerate scientists' development of effective therapies.

A recent study published in the international journal Nature Medicine titled "Differential roles of A42/40, p-tau231 and p-tau217 for Alzheimer's trial selection and disease monitoring" identified which blood tests best detect Alzheimer's disease in its early stages and which blood tests best detect the corresponding therapeutic effects. The discoveries might aid in the development of new therapies to slow the course of Alzheimer's disease in people.

Researchers analyzed 575 people from the BioFINDER cohort study for the paper, using a number of recently discovered blood tests for detecting the clinical symptoms and neurodegeneration of Alzheimer's disease. Researchers tested plasma in 242 people for up to six years, as well as cognitive assessment and magnetic resonance imaging studies.

Researchers analyzed 575 people from the BioFINDER cohort study for the paper, using a number of recently discovered blood tests for detecting the clinical symptoms and neurodegeneration of Alzheimer's disease. Researchers tested plasma in 242 people for up to six years, as well as cognitive assessment and magnetic resonance imaging studies.

The researchers revealed multiple blood biomarkers called p-tau231 and Aβ42/40, which are sufficient to help identify the pathological manifestations of Alzheimer's disease, even in participants without symptoms, and which might serve as a strategy to select the right individuals for this novel disease modification test, which currently requires expensive molecular imaging techniques or lumbar puncture to perform.

However, after 6 years of testing, investigators found that only p-tau217 was found to be involved in the pathological manifestations of Alzheimer's disease, the decline in cognitive performance function, and the exacerbation of brain atrophy typical of early Alzheimer's disease. Thus, p-tau217 may serve as an ideal marker to detect the disease-modifying effects associated with novel interventions, and this paper's study also has important implications for the use of blood tests in the recently reported anti-Aβ trial.

Unique blood tests, according to researcher Nicholas Ashton, may make a difference in clinical trials as the best way to help detect the pathological signs of Alzheimer's disease or to track disease development.

The results of this study suggest that p-tau217 may be the best test for disease monitoring of patients in clinical and experimental settings or contexts because of its longitudinal association with the development of Alzheimer's disease in the organism. A very important aspect of this study is that p-tau217 can help monitor pathological and cognitive changes in the body at a very early stage of the disease process.

Currently, in addition to improving the design of clinical trials, novel blood testing techniques may also revolutionize the diagnosis of early Alzheimer's disease, and in addition, p-tau217 could be further used in the future to monitor individual patients' responses to disease-modifying therapies in clinical practice.

A fan of biotechnology who likes to post articles in relevant fields regularly